Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

Similar articles for PubMed (Select 25120359)

1.

The application of EDTA in drug delivery systems: doxorubicin liposomes loaded via NH4EDTA gradient.

Song Y, Huang Z, Song Y, Tian Q, Liu X, She Z, Jiao J, Lu E, Deng Y.

Int J Nanomedicine. 2014 Aug 1;9:3611-21. doi: 10.2147/IJN.S64602. eCollection 2014.

2.

Preparation and characteristics of lipid nanoemulsion formulations loaded with doxorubicin.

Jiang SP, He SN, Li YL, Feng DL, Lu XY, Du YZ, Yu HY, Hu FQ, Yuan H.

Int J Nanomedicine. 2013;8:3141-50. doi: 10.2147/IJN.S47708. Epub 2013 Aug 19.

3.

Increased delivery of doxorubicin into tumor cells using extracellularly activated TAT functionalized liposomes: in vitro and in vivo study.

Yuan W, Kuai R, Ran R, Fu L, Yang Y, Qin Y, Liu Y, Tang J, Fu H, Zhang Q, Yuan M, Zhang Z, Gao F, He Q.

J Biomed Nanotechnol. 2014 Aug;10(8):1563-73.

PMID:
25016656
4.

A novel method to load topotecan into liposomes driven by a transmembrane NHâ‚„EDTA gradient.

Yang Y, Ma Y, Wang S.

Eur J Pharm Biopharm. 2012 Feb;80(2):332-9. doi: 10.1016/j.ejpb.2011.10.013. Epub 2011 Oct 24.

PMID:
22041601
5.

A novel hydrolysis-resistant lipophilic folate derivative enables stable delivery of targeted liposomes in vivo.

Huang Y, Yang T, Zhang W, Lu Y, Ye P, Yang G, Li B, Qi S, Liu Y, He X, Lee RJ, Xu C, Xiang G.

Int J Nanomedicine. 2014 Sep 29;9:4581-95. doi: 10.2147/IJN.S69115. eCollection 2014.

6.

Characterization and pharmacokinetics of a novel pirarubicin liposome powder.

Cong W, Liu Q, Chen X, Gao R, Lu J, Wang Y, Luo G.

Drug Dev Ind Pharm. 2010 Oct;36(10):1186-94. doi: 10.3109/03639041003695097.

PMID:
20515395
7.

pH-responsive polymer-liposomes for intracellular drug delivery and tumor extracellular matrix switched-on targeted cancer therapy.

Chiang YT, Lo CL.

Biomaterials. 2014 Jul;35(20):5414-24. doi: 10.1016/j.biomaterials.2014.03.046. Epub 2014 Apr 4.

PMID:
24709521
8.

Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.

Jung SH, Jung SH, Seong H, Cho SH, Jeong KS, Shin BC.

Int J Pharm. 2009 Dec 1;382(1-2):254-61. doi: 10.1016/j.ijpharm.2009.08.002. Epub 2009 Aug 8.

PMID:
19666094
9.

Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.

Gabizon A, Tzemach D, Gorin J, Mak L, Amitay Y, Shmeeda H, Zalipsky S.

Cancer Chemother Pharmacol. 2010 May;66(1):43-52. doi: 10.1007/s00280-009-1132-4. Epub 2009 Sep 25.

PMID:
19779718
10.

Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?

Mamidi RN, Weng S, Stellar S, Wang C, Yu N, Huang T, Tonelli AP, Kelley MF, Angiuoli A, Fung MC.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1173-84. doi: 10.1007/s00280-010-1406-x. Epub 2010 Jul 27.

PMID:
20661737
11.

Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes.

Xiang Y, Liang L, Wang X, Wang J, Zhang X, Zhang Q.

J Control Release. 2011 Jun 30;152(3):402-10. doi: 10.1016/j.jconrel.2011.03.014. Epub 2011 Mar 22.

PMID:
21435361
12.

Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.

Li X, Ding L, Xu Y, Wang Y, Ping Q.

Int J Pharm. 2009 May 21;373(1-2):116-23. doi: 10.1016/j.ijpharm.2009.01.023. Epub 2009 Feb 4.

PMID:
19429296
13.

Cholesterol derivatives based charged liposomes for doxorubicin delivery: preparation, in vitro and in vivo characterization.

Nie Y, Ji L, Ding H, Xie L, Li L, He B, Wu Y, Gu Z.

Theranostics. 2012;2(11):1092-103. doi: 10.7150/thno.4949. Epub 2012 Nov 13.

14.
15.

The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression.

Gao W, Lin Z, Chen M, Yang X, Cui Z, Zhang X, Yuan L, Zhang Q.

Int J Nanomedicine. 2014 Jul 21;9:3425-37. doi: 10.2147/IJN.S56070. eCollection 2014.

16.

A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug.

Lu WL, Qi XR, Zhang Q, Li RY, Wang GL, Zhang RJ, Wei SL.

J Pharmacol Sci. 2004 Jul;95(3):381-9.

17.

Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas.

Amin M, Badiee A, Jaafari MR.

Int J Pharm. 2013 Dec 31;458(2):324-33. doi: 10.1016/j.ijpharm.2013.10.018. Epub 2013 Oct 19.

PMID:
24148663
18.

Local targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicin.

Zhao C, Feng Q, Dou Z, Yuan W, Sui C, Zhang X, Xia G, Sun H, Ma J.

PLoS One. 2013 Sep 11;8(9):e73860. doi: 10.1371/journal.pone.0073860. eCollection 2013.

19.

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.

Gabizon A, Shmeeda H, Barenholz Y.

Clin Pharmacokinet. 2003;42(5):419-36. Review.

PMID:
12739982
20.

The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.

Yu KF, Zhang WQ, Luo LM, Song P, Li D, Du R, Ren W, Huang D, Lu WL, Zhang X, Zhang Q.

Int J Nanomedicine. 2013;8:2473-85. doi: 10.2147/IJN.S46962. Epub 2013 Jul 15.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk